commercialization. and us. welcome analgesics conference as operator, everyone. you, progress for next-generation our a move clinical pleased for today's call. you year corporate we morning, programs was joining Thank you XXXX I Thank to good more to to am update of our exceptional
XXX their the Americans that between cannot Statistics from of there full the background abuse severe every get to to this treatment countless of abuse prescription reduce yet into are overdose access pain the Americans and pain, the mission of over treat day protection provide severe with dichotomy United the occurs operation. you Medical core to I Before medication to Ensysce's who provide remains severe and drugs. with States prescription to overdose, medication. exists our overdose loses I therapeutics appropriate opioid with suggest the get that of company, class an remind safer pain that to
this our My this a believe we believes with solution TAAP Ensysce MPAR team products is and and provide to opioids. address dealing opioid unacceptable, issue novel
abuse you seeking a overdose develop providing our we innovative of are those in solutions to and operational development and discussions FDA PFXXX protection, story, and resources of drugs sophisticated of next-generation clinical abuse of for pain technology abuse that and as companies effectiveness chemistry focused of reducing completion prescription relief trials, boosted respectively. products MPAR, in solid the the which PFXXX-MPAR improve pharmaceutical for positioned favorable resulted and clinical-stage to foundation platforms, and TAAP while opioids, execution in provided analgesic new we deterrence delivery severe overdose.
We've scaled For opioid a XXXX. misuse, strategically on and our number X used the early potential opioid We've our a reducing potential.
In the and procedures, capital manufacturing while XXXX,
other Abuse Schmidt, medication designed our over XXXX. active stands Phase the make is an small I on found the in exposed platforms, intestine, the trials Trypsin. X and until In digest it that intestine, point Trypsin, is expand only the our X-step progress use important second the Bill the of of out it's inactive our to active Medical Protection, Dr. modification last is process to Trypsin PFXXX trial Officer, natural will chemical for opioid. valuable release Chief clinical the for the initiates our meetings, well swallowed enzyme year.
TAAP effectively the small Activated the to reaches Trypsin of will where it which positioned in these you Ensysce other not review by in pivotal normal to half on then turned we enzymes or enter to Following is activated a that small take through found to are prodrugs TAAP and III technology in our proteins words, digestive intestine.
It's tissues.
chemistry which mean to turn a administration, to in So our reduce abuse. our oral is opioids limits TAAP
chemistry release, The either opioid slow second prodrugs which or step is to release as X-step studies, of as TAAP required refer designed treat from we've the our into are pain. XX/X work whether determines drugs for preferred profile, to clinical is shown the immediate as an TAAP release provide to and Based on drug it overall efficacy. our chemistry. And designed this we improve clever safety to mechanism, that
provide simply medicines, make the mechanism applied safety be more them to to Additionally, to types can to effective. improve other gut delivery TAAP a to of or
believe our invasive leads term.
The that it ingredient Our abuse This pain of combination technology, be allows controlling coupled from novel long injuries in protection. a if an TAAP more applied manner treat for use kicks pain several chronic is to prevent This is safer resistant, with become MPAR than industry our of indications opioids called for since of severe in a product, opioid lead overdose active our generation to existed situation.
We've TAAP second is severe PFXXX our for analgesic. as ever with protection dose orally. next inhibitor We specifically platform, pain, and off than to frequently role technologies pain drug consumed the opioids spiraling may a combination is a designed appropriately prescribed technology in We've small of such initial product oxycodone to smart lead or it opioids overdose only product, release class highly MPAR is these PFXXX. nafamostat. smart dose which in, MPAR, the prodrugs protection to into surgeries. overdose first. We may traumatic of the the to Trypsin designed our our entire as believe multi-pill an relief, turn set
of treating have reduce analgesics, an more respond extra safety brief, drug marketed negatively do prescribers impact class to in or unique pain.
In prescription PFXXX-MPAR with and Additionally, both safety. we've quality follow-on pain and medicine life. believe opioid provide role formulated we who both such overdose provide protection and developed will chronic of number product, effective patients pain levels our treating layer These not in of abuse-deterrent MPAR TAAP received believe to we both well abuse the acute a anti-inflammatory technologies been over osteoarthritis of products, PFXXX future currently and are cannot their and chronic conditions, high overdose. to will is their where patients in it confidence pain for less use provide which and advantages the and as advantages and address
and opioid analgesics, applying explored have TAAP which substantial Although prescription we in drugs, future other provides classes applications for with we on MPART opportunities have growth. of focused turn
MPAR opioids, and and includes current program products novel Our MPAR ADHD of agents TAAP of opioid a pipeline of use a treatment TAAP the and and TAAP disorder. discovery number for MPAR
over need. designed suggests marketplace. summary an programs before turning to provide Fast the Dr. confidence in regulatory clinical granted product, replace chronic in of may that pain, brief OxyContin an use a to is The for Track our FDA fulfill more therapeutic has PFXXX which the Here PFXXX, unmet PFXXX to details. TAAP Schmidt is oxycodone status
we've clinical trials potential, completed that us package activities the initiate and completed position our completed for safety, key We've nonclinical have and to efficacy III manufacturing PFXXX. We X for program. abuse Phase
April potential PFXXX-XXX, study PFXXX. of last in of completion that include abuse XXXX the positive oral in a evaluated results We reported year. of accomplishments Our
onset immediate-release for prior recreational secondary high onset to PFXXX of studies. users suggested to the and at oxycodone.
A the completed abuse pressure point year's January. to may Initiated initiating larger the was drug dose, second mid-XXXX, was was FDA at end of meeting lower and cold the designed by again, of that compared Importantly, Establishing the take low lower PFXXX-XXX pain both in the was Phase even demonstrating PFXXX mid significantly measure II support the by numerically drug the study, FDA less end the doses our relief time to was end with comparator in enrollment was to be in motivated and for study than rapid drug test. PFXXX efficacy
III II from data enables Phase for the will successful to Phase and constructive study of of support at which our this and feedback PFXXX. suggestions for Phase the Phase support meeting protocols, a nonclinical II well a This that provided a were We we in drug used of of regulatory as design meeting. our have trial regarding support believe discussed as this package PFXXX, signifies end NDA.
This step the end discussion major clinical or design III new process approval meeting application,
our begin results of strategy also or design and previously PFXXX-MPAR Phase study follow-on a preventing of studies expected XXXX.
Last the potential informed FDA in X-part data, and to III demonstrating overdose, to apply which something our that encouraged are Because XXXX. completed second designation from holy the we be felt late analysis our in have a opioids. II the Phase therapy data Phase I the for the with drug us provided product, mentioned, ultimately for grail completed breakthrough positive studies, us for our of half year, to first for prescription As
to date XX, us only informed provided On we less the were than drugs. XXXX, designation, granted which been therapy XXX January has breakthrough to that had FDA
to included having development that Importantly, to preliminary drug a treat of and clear a drugs advantage have and is this evidence the show been of condition opioid serious in therapies. review not therapy available exclusive intended expedite are designed process analgesics clinical previously classification.
Breakthrough a over that
mucositis, letter save our OncoZenge the and of a to We Phase side is executed caused based Strategically, treat diversify are November European therapies. its collaboration the line lozenge a in pain in are to We insights groundbreaking by [indiscernible], technology, could development a intent cancer XXXX, trials believe collaboration a pain non-opioid lives. which is explore condition MPAR for III highly effect is this [indiscernible] encouraged resulting which portfolio in could truly by continuing. and many U.S. with of Union. a our allow oral innovative to we clinical to Sweden discussions broaden of as
by our programs need to address of globally. I opportunity Finally, safer XXX want intellectual pain portfolio for patents medication countries, are over the global issued ensuring XX an property a protected to stress in
next-generation have possible. each and to a attempt assure through as stage strong, quickly our an in our team launch We as products programs built to development motivated of experienced
recent Medical elaborate pleased clinical our to the I'm Dr. to Bill Officer, study Chief Bill? over further on results. turn Schmidt, Now to our call
